Estimating the effect of zidovudine on Kaposi's sarcoma from observational data using a rank preserving structural failure-time model.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Statistics in Medicine

• Publication date

  1998-05-30

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/(SICI)1097-0258(19980530)17:10<1073::AID-SIM789>3.0.CO;2-PPMID 9618771
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Causal diagrams for empirical research

  1995cited by this paper
• Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection

  1994cited by this paper
• Evaluation of the quality of life associated with zidovudine treatment in asymptomatic human immunodeficiency virus infection. The AIDS Clinical Trials Group.

  1994cited by this paper
• Causal estimation of time-varying treatment effects in observational studies: application to depressive disorder.

  1994cited by this paper
• Factors influencing survival after AIDS: report from the Multicenter AIDS Cohort Study (MACS).

  1994cited by this paper
• Zidovudine twice daily in asymptomatic subjects with HIV infection and a high risk of progression to AIDS: a randomized, double‐blind placebo‐controlled study

  1994cited by this paper
• Adjusting for differential rates of prophylaxis therapy for PCP in high- versus low-dose AZT treatment arms in an AIDS randomized trial

  1994cited by this paper
• The duration of zidovudine benefit in persons with asymptomatic HIV infection. Prolonged evaluation of protocol 019 of the AIDS Clinical Trials Group.

  1994cited by this paper
• Concorde lands.

  1994cited by this paper
• CONFOUNDING IN EPIDEMIOLOGIC STUDIES

  1993cited by this paper
• Trends in the incidence of outcomes defining acquired immunodeficiency syndrome (AIDS) in the Multicenter AIDS Cohort Study: 1985-1991.

  1993cited by this paper
• A method for the analysis of randomized trials with compliance information: an application to the Multiple Risk Factor Intervention Trial.

  1993cited by this paper
• Composite risk score for Kaposi's sarcoma based on a case-control and longitudinal study in the Multicenter AIDS Cohort Study (MACS) population.

  1993cited by this paper
• Estimating the causal effect of smoking cessation in the presence of confounding factors using a rank preserving structural failure time model.

  1993influential reference
• Epidemiologic analysis of Kaposi's sarcoma as an early and later AIDS outcome in homosexual men.

  1993influential reference
• [Double-blind dose-response study of zidovudine in AIDS and advanced HIV infection. Nordic Medical Research Councils' HIV Therapy Group].

  1993cited by this paper
• Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter

  1993cited by this paper
• Factors associated with Kaposi's sarcoma in a cohort of homosexual and bisexual men.

  1993cited by this paper
• Statistical Issues in Allowing for Noncompliance and Withdrawal

  1993cited by this paper
• A Note on the Kaplan—Meier Estimator

  1993cited by this paper
• On predictive causality in longitudinal studies

  1993cited by this paper
• Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. The European-Australian Collaborative Group.

  1993cited by this paper
• Recovery of Information and Adjustment for Dependent Censoring Using Surrogate Markers

  1992cited by this paper
• Influence of treatment with zidovudine (ZDV) on the long-term survival of AIDS patients.

  1992cited by this paper
• The effects on survival of early treatment of human immunodeficiency virus infection.

  1992cited by this paper
• Survival of Zidovudine-Treated Patients With AIDS Compared With That of Contemporary Untreated Patients

  1992cited by this paper
• Semiparametric estimation of an accelerated failure time model with time-dependent covariates

  1992cited by this paper
• Survival of zidovudine-treated patients with AIDS compared with that of contemporary untreated patients. Italian Zidovudine Evaluation Group.

  1992cited by this paper
• A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. Results of the Veterans Affairs Cooperative Study.

  1992cited by this paper
• G-Estimation of the Effect of Prophylaxis Therapy for Pneumocystis carinii Pneumonia on the Survival of AIDS Patients

  1992cited by this paper
• Quality-of-life evaluation in a clinical trial of zidovudine therapy in patients with mildly symptomatic HIV infection. The AIDS Clinical Trials Group.

  1992cited by this paper
• Estimation of the time-dependent accelerated failure time model in the presence of confounding factors

  1992influential reference
• Effect of zidovudine and Pneumocystis carinii pneumonia prophylaxis on progression of HIV-1 infection to AIDS. The Multicenter AIDS Cohort Study.

  1991cited by this paper
• Zidovudine and the natural history of the acquired immunodeficiency syndrome.

  1991cited by this paper
• Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter

  1991cited by this paper
• Multiple imputation in health-care databases: an overview and some applications.

  1991cited by this paper
• Zidovudine use in AIDS-free HIV-1-seropositive homosexual men in the Multicenter AIDS Cohort Study (MACS), 1987-1989.

  1991cited by this paper
• A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group.

  1990cited by this paper
• Zidovudine in Asymptomatic Human Immunodeficiency Virus Infection

  1990cited by this paper
• Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases.

  1990cited by this paper
• The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection a double-blind, placebo-controlled trial

  1990cited by this paper
• A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome

  1990cited by this paper
• The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group.

  1990cited by this paper
• Quality of life in a placebo-controlled trial of zidovudine in patients with AIDS and AIDS-related complex.

  1990cited by this paper
• Incidence of Kaposi's sarcoma in a cohort of homosexual men infected with the human immunodeficiency virus type 1. The Multicenter AIDS Cohort Study Group.

  1990cited by this paper
• Prolonged Zidovudine Therapy in Patients With AIDS and Advanced AIDS-Related Complex

  1989cited by this paper
• Confounding in epidemiologic studies. Response

  1989cited by this paper
• Research Methods in Occupational Epidemiology

  1989cited by this paper
• The control of confounding by intermediate variables.

  1989cited by this paper
• Modeling and variable selection in epidemiologic analysis.

  1989cited by this paper
• Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. AZT Collaborative Working Group.

  1989cited by this paper
• Explanatory and pragmatic estimates of the treatment effect when deviations from allocated treatment occur.

  1988cited by this paper
• Survival experience among patients with AIDS receiving zidovudine. Follow-up of patients in a compassionate plea program.

  1988cited by this paper
• Effect of T4 count and cofactors on the incidence of AIDS in homosexual men infected with human immunodeficiency virus.

  1987cited by this paper
• Addendum to “a new approach to causal inference in mortality studies with a sustained exposure period—application to control of the healthy worker survivor effect”

  1987cited by this paper
• Errata to “a new approach to causal intefence in mortality studies with a sustained exposure period—application to control of the healthy worker survivor effect” Mathl Modelling 7(9–12), 1393–1512 (1986)

  1987cited by this paper
• A graphical approach to the identification and estimation of causal parameters in mortality studies with sustained exposure periods.

  1987cited by this paper
• The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.

  1987cited by this paper
• The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.

  1987cited by this paper
• The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants.

  1987cited by this paper
• A new approach to causal inference in mortality studies with a sustained exposure period—application to control of the healthy worker survivor effect

  1986cited by this paper
• The need for randomization in the study of intended effects.

  1985cited by this paper
• The Consequences of Adjustment for a Concomitant Variable that Has Been Affected by the Treatment

  1984cited by this paper
• Conditional Permutation Tests and the Propensity Score in Observational Studies

  1984cited by this paper
• The central role of the propensity score in observational studies for causal effects

  1983cited by this paper
• Maximum Likelihood Estimation of Misspecified Models

  1982cited by this paper
• Control of confounding in the assessment of medical technology.

  1980cited by this paper
• Regression models and life tables (with discussion

  1972cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper
• Survival Curve for Cancer Patients Following Treatment

  1952cited by this paper
• Popliteal Aneurysm

  1937cited by this paper

• Estimating Effect of Obesity on Stroke Using G‐Estimation: The ARIC study

  2019cites this paper
• Accounting for Time-Varying Confounding in the Relationship Between Obesity and Coronary Heart Disease: Analysis With G-Estimation The ARIC Study

  2018cites this paper
• A Simple Model Allowing Modification of the Effect of a Randomized Intervention by Post-Randomization Variables

  2017cites this paper
• Estimating the average treatment effect on survival based on observational data and using partly conditional modeling

  2017cites this paper
• A Simple Model Allowing Modification of the Effect of a Randomized Intervention by Post-Randomization Variables

  2017cites this paper
• Survival Benefit of Lung Transplantation in the Modern Era of Lung Allocation

  2016cites this paper
• Is Early Smoking a Causal Risk Factor for Later Cognitive Impairment? A 20-year Prospective Study with Time-varying Propensity Score Matching Based on Random Intercept and Slope

  2016cites this paper
• Healthy worker survivor bias in the Colorado Plateau uranium miners cohort.

  2015cites this paper
• Comparative Effectiveness Research/Health Technology Assessment (HTA) Analyzing Overall Survival in Randomized Controlled Trials with Crossover and Implications for Economic Evaluation

  2014cites this paper
• Healthy worker survivor bias in a cohort of uranium miners from the Colorado Plateau

  2014cites this paper
• Chapter 14 G-estimation for Accelerated Failure Time Models

  2012cites this paper
• Structural nested models, g-estimation, and the healthy worker effect: the promise (mostly unrealized) and the pitfalls.

  2012cites this paper
• Modern Methods for Epidemiology

  2012cites this paper
• A review of causal estimation of effects in mediation analyses

  2012cites this paper
• G-estimation for Accelerated Failure Time Models

  2012cites this paper
• The Promise (Mostly Unrealized) and the Pitfalls

  2012cites this paper
• The Effect of Winning an Oscar Award on Survival: Correcting for Healthy Performer Survivor Bias With a Rank Preserving Structural Accelerated Failure Time Model

  2011cites this paper
• Causal models for estimating the effects of weight gain on mortality

  2008cites this paper
• Estimation of the marginal survival time in the presence of dependent competing risks using inverse probability of censoring weighted (IPCW) methods

  2008cites this paper
• Causal mediation analyses for randomized trials

  2008cites this paper
• Causal Mediation Analyses with Rank Preserving Models

  2007cites this paper
• Estimation of treatment effect adjusting for dependent censoring using the IPCW method: an application to a large primary prevention study for coronary events (MEGA study)

  2007cites this paper
• Propensity score for the analysis of observational data: an introduction and an illustrative example

  2006cites this paper
• Propensity Score Matching with Time‐Dependent Covariates

  2005cites this paper
• Adjusting for differential proportions of second‐line treatment in cancer clinical trials. Part I: Structural nested models and marginal structural models to test and estimate treatment arm effects

  2004cites this paper
• Causal logistic models for non‐compliance under randomized treatment with univariate binary response

  2003cites this paper
• Use of a marginal structural model to determine the effect of aspirin on cardiovascular mortality in the Physicians' Health Study.

  2002cites this paper
• Estimating the effect of cardiovascular risk factors on all-cause mortality and incidence of coronary heart disease using G-estimation: the atherosclerosis risk in communities study.

  2002cites this paper
• Planning an Observational Study

  2002cites this paper
• An overview of relations among causal modelling methods.

  2002cites this paper
• Balanced Risk Set Matching

  2001cites this paper
• Human herpesvirus 8 and Kaposi's sarcoma in persons infected with human immunodeficiency virus.

  2000cites this paper
• Confounding by indication: the case of calcium channel blockers

  2000cites this paper
• Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor

  2000cites this paper
• Accelerated failure time models for non-ignorable non-compliance in randomized studies

  2000cites this paper
• Invited commentary: propensity scores.

  1999cites this paper